Comparative Pharmacology
Head-to-head clinical analysis: ANDROID F versus TESTIM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANDROID F versus TESTIM.
ANDROID-F vs TESTIM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fingolimod is a sphingosine 1-phosphate receptor modulator that sequesters lymphocytes in lymph nodes, reducing central nervous system immune cell infiltration.
Testosterone replacement therapy; binds to and activates androgen receptors, modulating gene expression leading to male sexual development and maintenance of secondary sexual characteristics.
Adults: 1 tablet (methyltestosterone 2.5 mg, ethinyl estradiol 0.025 mg) orally once daily, with food.
Apply 5 g (1 tube) of 1% gel to clean, dry, intact skin of the shoulders, upper arms, or abdomen once daily, preferably in the morning. Dosage may be adjusted to 10 g (2 tubes) depending on clinical response. Apply immediately after opening and avoid bathing or swimming for at least 30 minutes.
None Documented
None Documented
2.5-3.5 hours (terminal half-life); oral administration may require multiple daily doses for stable levels.
Terminal elimination half-life of testosterone from serum is approximately 10-100 minutes after intravenous administration, but after transdermal application of Testim, the apparent half-life is longer (around 1-2 hours) due to continued absorption from the skin depot. The half-life of active metabolites (e.g., dihydrotestosterone) is about 2-3 hours.
Primarily renal (90% as glucuronide and sulfate conjugates, 10% unchanged); small amount biliary/fecal.
Testosterone is primarily excreted in urine as glucuronide and sulfate conjugates (approximately 90%), with about 6% excreted in feces via bile. Less than 1% is excreted unchanged.
Category C
Category C
Androgen/Estrogen Combination
Androgen